Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.

abstract：PURPOSE:To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS:Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW)...

journal_title：Breast cancer research and treatment

authors： Silver MI,Klein W,Samimi G,Minasian L,Loud J,Roberts MC

更新日期：2019-02-01 00:00:00

abstract：:To determine whether atypical antipsychotics, when compared to typical antipsychotics, increase the risk of breast cancer. We conducted a retrospective cohort study using a nested case-control analysis within the United Kingdom General Practice Research Database population. We identified all female patients prescribed...

journal_title：Breast cancer research and treatment

authors： Azoulay L,Yin H,Renoux C,Suissa S

更新日期：2011-09-01 00:00:00

abstract：:A number of endocrine treatments for advanced breast cancer seem to affect serum insulin-like growth factor I (IGF-I). The aim of our study was to investigate IGF-I levels in 33 postmenopausal patients with metastatic disease receiving the selective aromatase inhibitor 4-hydroxyandrostenedione: 250 mg (16 patients) or...

journal_title：Breast cancer research and treatment

authors： Ferrari L,Zilembo N,Bajetta E,Buzzoni R,Noberasco C,Martinetti A,Celio L,Galante E,Orefice S,Cerrotta AM

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. METHODS:Of the 53,670 patients registered between 2004 and 2006 and su...

journal_title：Breast cancer research and treatment

authors： Kataoka A,Iwamoto T,Tokunaga E,Tomotaki A,Kumamaru H,Miyata H,Niikura N,Kawai M,Anan K,Hayashi N,Masuda S,Tsugawa K,Aogi K,Ishida T,Masuoka H,Iijima K,Kinoshita T,Nakamura S,Tokuda Y

更新日期：2016-11-01 00:00:00

abstract：:Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient targeted therapy is warra...

journal_title：Breast cancer research and treatment

authors： Girgert R,Emons G,Gründker C

更新日期：2012-07-01 00:00:00

abstract：:Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

journal_title：Breast cancer research and treatment

authors： Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

更新日期：2012-06-01 00:00:00

abstract：:Estrogen plus progestin hormone therapy has been associated with increased breast proliferation, breast density, and breast cancer risk in postmenopausal women, beyond that seen with estrogen alone. The goal of this study was to evaluate progestogen effects on gene expression profiles in the breast contributing to thi...

journal_title：Breast cancer research and treatment

authors： Wood CE,Register TC,Cline JM

更新日期：2009-03-01 00:00:00

abstract：:To determine whether recent genome-wide association studies that reported 45 susceptibility loci in European women are also risk factors for breast cancer in Chinese women. We selected and genotyped 40 single nucleotide polymorphisms (SNPs) using the Sequenom iPlex platform in a female Chinese cohort of 2,901 breast c...

journal_title：Breast cancer research and treatment

authors： Zhang B,Li Y,Li L,Chen M,Zhang C,Zuo XB,Zhou FS,Liang B,Zhu J,Li P,Huang ZL,Xuan H,Li W,Chen ZD

更新日期：2014-08-01 00:00:00

abstract：PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

journal_title：Breast cancer research and treatment

authors： Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

更新日期：2020-11-18 00:00:00

abstract：:Published data on the association between Xeroderma Pigmentosum complementation group D (XPD) Lys751Gln polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association be...

journal_title：Breast cancer research and treatment

authors： Qiu LX,Yao L,Zhang J,Zhu XD,Zhao XM,Xue K,Mao C,Chen B,Zhan P,Yuan H,Hu XC

更新日期：2010-11-01 00:00:00

abstract：:Transforming growth factor-β1 (TGF-β1) is negative regulator of cell proliferation and the cell cycle, and plasma levels of TGF-β1 are twice as high in TGF-β1 -509 T homozygotes as in -509 C homozygotes. Published studies on the association between the TGF-β1 gene -509 C/T polymorphism and breast cancer risk are incon...

journal_title：Breast cancer research and treatment

authors： Woo SU,Park KH,Woo OH,Yang DS,Kim AR,Lee ES,Lee JB,Kim YH,Kim JS,Seo JH

更新日期：2010-11-01 00:00:00

abstract：:We previously identified a polymorphism in the human estrogen receptor (ER) gene, within the coding region for the protein's amino terminal B-domain. In estrogen receptor-positive (ER+) breast tumors, the variant allele was preferentially associated with lower levels of ER, and was clinically correlated with frequent ...

journal_title：Breast cancer research and treatment

authors： Schmutzler RK,Sanchez M,Lehrer S,Chaparro CA,Phillips C,Rabin J,Schachter B

更新日期：1991-10-01 00:00:00

abstract：BACKGROUND:Staging procedures used to detect metastatic breast cancer at the time of diagnosis are bone scan (BS), chest X-ray (CXR), liver ultrasonography (LUS) and laboratory parameters (LP). These procedures are expensive and not all patients need them. We aimed to identify groups of patients with different risks fo...

journal_title：Breast cancer research and treatment

authors： Ravaioli A,Pasini G,Polselli A,Papi M,Tassinari D,Arcangeli V,Milandri C,Amadori D,Bravi M,Rossi D,Fattori PP,Pasquini E,Panzini I

更新日期：2002-03-01 00:00:00

abstract：:Fibroblast growth factor receptor 2 (FGFR2) is a member of a receptor tyrosine kinase gene superfamily, involved in cell growth, invasiveness, motility, and angiogenesis, which has attracted considerable attention as a candidate gene for breast cancer (BC) since it was first identified through genome-wide association ...

journal_title：Breast cancer research and treatment

authors： Wang H,Yang Z,Zhang H

更新日期：2013-01-01 00:00:00

abstract：:Sex Hormone-Binding Globulin (SHBG), the plasma carrier for androgens and estradiol, inhibits the estradiol-induced proliferation of breast cancer cells through its membrane receptor, cAMP, and PKA. In addition, the SHBG membrane receptor is preferentially expressed in estrogen-dependent (ER+/PR+) breast cancers which...

journal_title：Breast cancer research and treatment

authors： Becchis M,Frairia R,Ferrera P,Fazzari A,Ondei S,Alfarano A,Coluccia C,Biglia N,Sismondi P,Fortunati N

更新日期：1999-03-01 00:00:00

abstract：:It is common belief among physicians the idea that breast cancer was not diagnosed centuries ago. Nevertheless, there are reports suggesting that old masters and even common people knew this dramatic disease. In the 16th and 17th centuries, famous artists painted things exactly as they saw them. This allows the detect...

journal_title：Breast cancer research and treatment

authors： Grau JJ,Estrach T

更新日期：2008-09-01 00:00:00

abstract：:The purpose of this study was to examine the urban-rural difference in breast cancer mortality between 2002 and 2008 in China. A longitudinal analysis of mortality data was performed. Mortality data were extracted from Chinese Health Statistics Yearbook. Linear regression was used to examine the statistical significan...

journal_title：Breast cancer research and treatment

authors： He M,Guo Q,Hu G

更新日期：2011-02-01 00:00:00

abstract：:It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we ev...

journal_title：Breast cancer research and treatment

authors： Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

更新日期：2012-04-01 00:00:00

abstract：:Numerous allelic variants identified in the familial breast cancer and DNA repair genes BRCA1 and BRCA2 are of unknown impact on protein function or clinical relevance, referred to as unclassified variants (UCV). Lymphocytes from pathogenic BRCA1/2 mutation carriers exhibit an increased level of chromosomal damage aft...

journal_title：Breast cancer research and treatment

authors： Becker AA,Graeser MK,Landwehr C,Hilger T,Baus W,Wappenschmidt B,Meindl A,Weber RG,Schmutzler RK

更新日期：2012-08-01 00:00:00

abstract：:Identification and characterization of tumor subtypes using gene expression profiles of triple negative breast cancer patients. Microarray data of four breast cancer studies were pooled and evaluated. Molecular subtype classification was performed using random forest and a novel algorithm for feature extraction via co...

journal_title：Breast cancer research and treatment

authors： Koch M,Hanl M,Wiese M

更新日期：2012-08-01 00:00:00

abstract：PURPOSE:Rates of contralateral prophylactic mastectomy (CPM) have increased over the last decade; it is important for surgeons and hospital systems to understand the economic drivers of increased costs in these patients. This study aims to identify factors affecting charges in those undergoing CPM and reconstruction. ...

journal_title：Breast cancer research and treatment

authors： Bucknor A,Chattha A,Ultee K,Wu W,Kamali P,Bletsis P,Chen A,Lee BT,Cronin C,Lin SJ

更新日期：2017-09-01 00:00:00

abstract：:Co-transfection studies indicate that HER2 (erbB-2) overexpression results in the phosphorylation and enhanced transcriptional activity of the androgen receptor (AR). This amplification of AR action is further enhanced by the expression of ARA70, a putative co-activator with a predilection for the AR. Because androgen...

journal_title：Breast cancer research and treatment

authors： Kollara A,Kahn HJ,Marks A,Brown TJ

更新日期：2001-06-01 00:00:00

abstract：PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

journal_title：Breast cancer research and treatment

authors： Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implica...

journal_title：Breast cancer research and treatment

authors： Leon-Ferre RA,Polley MY,Liu H,Gilbert JA,Cafourek V,Hillman DW,Elkhanany A,Akinhanmi M,Lilyquist J,Thomas A,Negron V,Boughey JC,Liu MC,Ingle JN,Kalari KR,Couch FJ,Visscher DW,Goetz MP

更新日期：2018-01-01 00:00:00

abstract：:We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

journal_title：Breast cancer research and treatment

authors： Kokko R,Hakama M,Holli K

更新日期：2005-10-01 00:00:00

abstract：:We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

journal_title：Breast cancer research and treatment

authors： Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

更新日期：2006-08-01 00:00:00

abstract：:Identification of novel targets for the treatment of basal-like breast cancer is essential for improved outcomes in patients with this disease. This study investigates the association of MMP7 expression and MMP7 promoter methylation with subtype and outcome in breast cancer patient cohorts. Immunohistochemical analysi...

journal_title：Breast cancer research and treatment

authors： Sizemore ST,Sizemore GM,Booth CN,Thompson CL,Silverman P,Bebek G,Abdul-Karim FW,Avril S,Keri RA

更新日期：2014-07-01 00:00:00

abstract：:We have previously shown that the anti-proliferative effect of retinoic acid in human breast cancer cell line MCF-7 is dependent on HES-1 expression. Here we show that retinoic acid induces HES-1 expression via upregulation of transcription factor SOX9. By expressing a dominant negative form of SOX9, disrupting endoge...

journal_title：Breast cancer research and treatment

authors： Müller P,Crofts JD,Newman BS,Bridgewater LC,Lin CY,Gustafsson JA,Ström A

更新日期：2010-04-01 00:00:00

abstract：:Bone metastasis is a common and serious complication in advanced cancers such as breast cancer, prostate cancer, and multiple myeloma. Agents that prevent bone loss could be used to develop an alternative therapy for bone metastasis. RANKL, a member of the tumor necrosis factor superfamily, has been shown to play a si...

journal_title：Breast cancer research and treatment

authors： Zhai Z,Qu X,Yan W,Li H,Liu G,Liu X,Tang T,Qin A,Dai K

更新日期：2014-02-01 00:00:00

abstract：:Seventy-two patients underwent dye-guided or dye- and gamma probe-guided sentinel lymphadenectomy (SLND) followed by complete axillary lymph node dissection (ALND). The results of imprint cytology, frozen sections, and permanent sections of the sentinel lymph node (SLN) were compared to each other and to the histologi...

journal_title：Breast cancer research and treatment

authors： Noguchi M,Bando E,Tsugawa K,Miwa K,Yokoyama K,Nakajima K,Michigishi T,Tonami N,Minato H,Nonomura A

更新日期：1999-09-01 00:00:00